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Introduction
Ellagitannins (ETs) and ellagic acid (EA) derivatives are naturally occurring polyphenols found in pomegranate, berries, and nuts. It has been reported that EA exerts various health benefits including free radical scavenger activity and anti-proliferative effects in various types of cancer in vivo and in vitro [1] [2] [3] . There is a substantial body of evidence that supplementation with pure EA alone or consumption of EA-enriched fruits and nuts attenuates body fat mass and liver lipids [4] [5] [6] , suggesting that EA possesses lipid-lowering characteristics. Supporting this, our group has recently reported that EA reduces Molecular Nutrition & Food Research This article is protected by copyright. All rights reserved. 4 adipogenesis through the inhibition of co-activator arginine methyltransferase 1 (CARM1) in primary human adipogenic stem cells (hASCs) [7] , alters lipid mechanisms both in human adipocytes and hepatocytes [8] , and normalizes HF-diet mediated obesity and metabolic dysfunction [6, 8] .
Likewise to many other health-promoting polyphenolic compounds, low bioavailability of EA remains paradoxical. Oral administration of pure EA or EA-containing products in both rodents and humans showed that ~ 1 M of EA can be found in plasma or tissues [9, 10] . This is attributed to the fact that EA undergoes extensive metabolic transformation prior to absorption [11] . In the intestinal lumen, EA is extensively metabolized by gut microbes producing a series of metabolites called urolithins (Uro). Uro are characterized by a common 6H-dibenzo[b,d]-pyran-6-one nucleus and a decreasing number of phenolic hydroxyl groups (UroD UroC UroA or iso-UroA UroB) (Fig. 1A ) [12] . Among Uro species, UroA is the major metabolite observed in humans while Iso-UroA and UroB conjugates are also observed in some, but not all, humans [12, 13] . As the result of microbial actions, EA is converted into bioavailable Uro which can reach significant concentrations in plasma and tissues [12, [14] [15] [16] .
Recently, several studies have demonstrated that Uro have metabolic characteristics of EA showing anti-inflammatory [17] , anti-cancer [18, 19] , anti-glycative [20] and antioxidant [21] properties. However, it is largely unknown if Uro have TG-lowering effects by altering lipid metabolism. To address this issue, we investigated the effects of individual Uro on lipid metabolism in human adipocytes and confirmed augmented fatty acid (FA) oxidation in human hepatoma Huh7 cells. Here, we are the first to report that Uro (30 M) This article is protected by copyright. All rights reserved. 5
possess biological activities to downregulate adipogenesis and lipogenesis similar to EA in human adipocytes. We also demonstrated that Uro alter lipid metabolism via AMPK activation.
Materials and methods

Chemical reagents
All cell culture supplies were purchased from Fisher Scientific. Fetal bovine serum (FBS) and penicillin-streptomycin were purchased from Cellgro Mediatech, Inc. (Herndon, VA). Rosiglitazone (BRL49653) was purchased from Cayman Chemical (Ann Arbor, MI). EA was purchased from Sigma-Aldrich (St. Louis, MO). UroA, B, C, D and iso-UroA were obtained as described elsewhere [22] . All other chemicals and reagents were purchased from Sigma Chemical Co (St. Louis, MO), unless otherwise stated.
Cell culture
All protocols and procedures were approved by the Institutional Review Board at the University of Nebraska-Lincoln. For isolation of human adipogenic stem cells (hASCs), abdominal adipose tissue was obtained from females with a body mass index (BMI) of ~30 during liposuction or abdominal plastic surgeries. Isolation of hASCs and differentiation of adipocytes was conducted as we described previously [7, 8] . Each independent experiment was repeated at least three times using a pool of hASCs from three or four human subjects to avoid individual variation. Huh7 cells were maintained in Dulbecco's modification of This article is protected by copyright. All rights reserved. 6
Eagle's medium (DMEM) containing 1% L-glutamine, 10% fetal bovine serum, 100 units/ml penicillin, 100 g/ml streptomycin in 5% CO2 at 37°C. The medium was changed every 3 days.
Cell viability assay
The cytotoxic effects of Uro and EA were determined using the XTT Cell Viability Kit hours at 37℃ before measurement of OD 450 nm using a Synergy™ H1 hybrid plate reader (BioTek, Winooski, VT).
Lipid accumulation
To measure the lipid accumulation in human adipocytes, cells were fixed with 10% 
Western blot analysis
To prepare total cell lysates, monolayers of hASC cultures and fully differentiated adipocytes were scraped with ice cold radioimmune precipitation assay (RIPA) buffer (Thermo Scientific) containing protease inhibitors (Sigma) and phosphatase inhibitors (2 mM Na 3 VO 4 , 20 mM β-glycerophosphate and 10 mM NaF). Proteins were fractionated using 8 or 10% SDS-PAGE, transferred to PVDF membranes, and incubated with the relevant antibodies. Chemiluminescence from ECL (Western Lightning) solution was detected using a This article is protected by copyright. All rights reserved. 9
Statistical analysis
Results are presented as means ± SEM. The data were statistically analyzed using one-way ANOVA with Tukey's multiple comparison tests. All analyses were performed with GraphPad Prism 5 (Version 5.04). 
Results
Urolithins inhibit adipogenesis in hASCs
We previously demonstrated that EA suppressed adipogenic differentiation in hASCs [7, 8] . To determine whether Uro were able to inhibit adipogenesis, 30 M individual Uro was added to hASCs during differentiation ( Fig. 2A) . The presence of Uro, but not iso-UroA, This article is protected by copyright. All rights reserved. 10 caused a significant reduction of TG accumulation measured by ORO staining ( Fig. 2A, B ).
The rank order of anti-adipogenic potential was UroA, C, D >> UroB > iso-UroA as assessed by TG accumulation using ORO staining. To further confirm the anti-adipogenic effects of Uro, adipogenic gene and protein expression levels were determined by qPCR and Western blot. Consistent with reduced TG accumulation, Uro treatment, except for iso-UroA, significantly suppressed adipogenic gene expression including PPAR and Fas (Fig. 2C ).
Adipogenic protein expression including aP2, Fas, PPAR, and C/EBP were also dramatically reduced in cultures treated with UroC and D and to a lesser magnitude with UroA ( Fig. 2D ).
To gain insight into whether Uro alter epigenetic marks similar to their parent compound EA [7] , histone 3 arginine 17 methylation (H3R17me2), and histone acetylation (AcH3) levels were examined. Interestingly, only UroC incubation, but no other Uro treatment, markedly suppressed the epigenetic markers (Supplemental Fig. 1 ).
Several phytochemicals are known to inhibit adipogenesis through the mechanism related to AMPK activation [25] [26] [27] [28] . AMPK is a major energy-sensor triggering a variety of catabolic processes and suppressing anabolic pathways simultaneously [29] . Treatment with EA increased AMPK phosphorylation dose-dependently (Fig. 2E ). To further identify whether Uro are also able to regulate AMPK activation, we examined phosphorylated and total AMPK levels. Interestingly, UroA, C, and D increased phosphorylated AMPK levels ( Fig. 2F) , which is consistent with the trend of the anti-adipogenic role of Uro.
Urolithins attenuate lipid accumulation in cultures of human adipocytes
Next, we asked whether Uro could antagonize adipocyte hypertrophy. To examine this, fully differentiated cultures of human adipocytes were exposed to Uro for seven days This article is protected by copyright. All rights reserved. 11
based on the experimental design (Fig. 3A, upper) . Exposure to 30 M Uro for seven days caused a significant reduction of TG accumulation, but not UroB and iso-UroA, as measured by ORO staining (Fig. 3A, below) . To test whether the reduction of TG accumulation was aligned with lipogenic transcriptional inhibition, we measured mRNA expressions. Uro treatment (A, C, and D) decreased lipogenic-specific gene expression including PPAR, Fas, adipose triglyceride lipase (ATGL) and steroyl-CoA desaturase-1 (SCD-1) compared to vehicle control (Fig. 3B ). UroC and D are potent EA-derived metabolites in upregulating AMPK activation in fully differentiated adipocytes (Fig. 3C ).
Urolithins regulate lipid metabolisms in cultures of human adipocytes
We then investigated whether lipid-lowering effects of Uro are due to an alteration of UroA, B, C, D, iso-UroA and EA treatment slightly affected cell bioavailability (~80%) but no specific cytotoxic effects were observed in up to 30 M concentrations (Fig. 5A) 5E ).
Discussion
Uro are gut microbiota-derived metabolites of EA and ETs. Different types of Uro (Fig. 1A) are produced by intestinal microbes, which may reflect the metabolic health status of hosts [13] . Although it has long been known that Uro may be critical determinants of the effectiveness of EA supplementation, it is largely unknown whether different species of Uro possess different biological activities in humans. Recently, a number of studies have reported the unique role of Uro species by evaluating their efficacy in various cancer [18, 30] , and inflammatory diseases [17, 31] . One recent study [13] and other unpublished This article is protected by copyright. All rights reserved. 13 observation correlate a higher prevalence of the metabotype producing iso-UroA and UroB in overweight and obese individuals, while UroA is associated with healthy individuals.
However, no studies have been conducted to determine the function of individual Uro in human obesity. The present study was specifically designed to assess the role of individual Uro species in manipulating lipid metabolism using primary human adipocytes. Here we demonstrated that UroA, C and D are effective in attenuating TG accumulation and increasing FA oxidation through AMPK-dependent mechanisms in primary human adipocytes as well as in Huh7 cells. These results may provide a novel insight into a 'structure and function' relationship among Uro, which may lead to a unique therapeutic design to control adiposity.
An accumulating body of evidence suggests that the gut microbial community affects the host's energy homeostasis by altering energy metabolism [32] [33] [34] . To corroborate this concept, production of different Uro may comprise a part of the mechanism in which gut microbes regulate the host's energy metabolism. In other words, metabolically healthy subjects may possess microbiota that are able to generate mainly active Uro such as UroA (i.e. subjects belonging to the so-called 'metabotype A' [13] ). In contrast, metabolically unhealthy humans may have bacterial communities producing UroA but also other less active urolithins such as iso-UroA and UroB (i.e., subjects with 'metabotype B' [13] ). García-Villalba et al. reported that there were compositional differences in the gut microbiome between human subjects who produce UroA (effective Uro) and who produce iso-UroA and B (less active Uro) [11, 35] . Also, subjects who have a higher risk of chronic illness produce iso-UroA and UroB [13] , the two inactive EA metabolites in our experimental setting (Fig. 2- 
4). Recently, Gordonibacter urolithinfaciens sp. nov. has been identified as a novel bacterial
This article is protected by copyright. All rights reserved. 14 species responsible for converting EA into UroM5 and UroC [36] . This bacterium belongs to the family Coriobacteriaceae a family that is associated with benefits in obesity [37] . Since the bacterial phylum that specifically transform EA or its intermediate metabolites into UroA vs. iso-UroA/UroB have not yet been identified, it could be of interest for future studies.
Numerous studies in animals and humans have demonstrated that free EA can be found in no more than 100 nM concentrations after oral administration of EA or ETcontaining foods [9, 10] . The low bioavailability of EA is largely due to limited solubility and its rapid metabolism into Uro by the gut microbiome [10] . As a metabolic consequence, Uro can reach relevant concentrations in the blood stream and human colon microenvironment [12, 14] . Although Uro might not be accumulated in metabolic tissues, i.e., adipose tissue, liver or muscle, a few reports have shown that Uro are able to circulate enterohepatically [38] . In terms of cytotoxicity, 50-150 M of Uro have exhibited anti-cancer properties by inhibiting cell proliferation and cell cycle progression in various carcinoma cell lines [18, 39] .
In this study, we first assessed the cytotoxicity of 30 M concentration in hASCs as well as differentiated cultures of adipocytes. However, Uro treatment does not seem to affect cell viability in non-carcinogenic cells [31] , implying that Uro might induce apoptosis in malignant tumor cells but not in mitogenically quiescent cells. Consistently, our results
showed that 30 M Uro treatments showed no sign of cytotoxicity in time frames of both early-and terminal-stages of adipogenesis. The anti-adipogenic and anti-lipogenic effects of Uro in our study were not due to the apoptotic property of Uro (Fig. 1B-G our assay conditions using 30 M of Uro is rationed based on the facts that 1) treatment of high dose of polyphenolics are valid when we characterize the biological significance of polyphenolic molecules (such as resveratrol) using in vitro systems, and 2) in the context of urolithins, the reported systemic concentrations of urolithins can reach up to micro molar levels [14] . These concentrations can be much higher in the gut [16] and also in the bile [38] .
In our study, 30 M of Uro treatment in adipocytes was associated with at least three metabolic outcomes: 1) attenuating adipogenesis, 2) inhibiting TG accumulation, and 3)
increasing AMPK activation.
The major distinctive metabolic consequences that we immediately noticed was that Uro differentially impacted adipogenesis in hASCs. UroA, C and D treatment, but not isoUroA or UroB, interfered with adipogenic differentiation (Fig. 2) . Recently, estrogen receptor  (ER) has been proposed as a negative regulator of adipocyte development in preadipocytes [40] . Interestingly, Larrosa et al. showed that UroA possesses higher ER binding affinity than UroB in breast cancer cells suggesting that UroA plays a role as a phytoestrogen (ER binding affinity of UroA:  > . In terms of structural differences, EA, UroA, C and D have common hydroxyl position at number 8 carbon (-OH at C8) compared to iso-UroA or UroB. González-Sarrías et al. also proposed that phase II phenolic enzymatic activities are crucially affected by reactive moieties such as hydroxyl groups [18] .
This interpretation aligns with our results showing that the absence of -OH moiety at C8
position of Uro, due to isomerism (iso-UroA) or metabolic loss (UroB) is inversely correlated with the ability to downregulate adipogenic differentiation. Thus, it may also be reasonable This article is protected by copyright. All rights reserved. 16 to assume that -OH moiety at C8 position might affect binding affinity to ER. Further studies are necessary to validate the aforementioned structure-function relationship in adipogenic differentiation. The other possible mechanism of Uro's anti-adipogenic effect could be explained by its ability to alter epigenetic marks. We have previously shown that EA modified histone methyltransferase (CARM1) enzyme activities during adipogenesis [7] .
Consistently, we were able to observe that UroC downregulated histone arginine 17 methylation during adipogenesis (Supplemental Fig. 1 ). UroC was also reported to reduce TNF-induced inflammation through inhibition of histone acetyltransferase (HAT) activity in the monocyte cell [42] . At this point, we speculate UroC may have stronger DNA binding affinity comparable to EA [43, 44] than the other Uro intermediates, conferring ability to edit epigenetic codes such as histone methylation and/or acetylation. Collectively, differential regulation of adipogenesis by Uro likely originates from their structural difference of Uro. Future studies are required to scrutinize the metabolic contribution of C8 hydroxyl moiety of Uro to ER binding affinity, CARM1 activity, and AMPK activation.
Subsequently, we examined the potential role of Uro in regulating lipid metabolism in fully differentiated adipocytes and hepatoma Huh7 cells. Previously, we showed that EA modulates global lipid metabolism by attenuating TG accumulation in both adipocytes and hepatocytes [8] . This TG-lowering effect seems to be conserved in mammalian cells [8] and even in yeasts (data not shown). In this current research setting, we found that Uro effectively reduced de novo synthesis and TG esterification and enhanced FA oxidation in adipocytes (Fig. 3, 4) . These data revealed that EA apparently gradually lost its ability to downregulate lipid accumulation while EA is successively metabolized by gut microbes until its conversion to the least effective UroB. Therefore, the potency of Uro in regulating TG Lastly, we have found AMPK activation could be a link mediating anti-adipogenic and antilipogenic effects of Uro. AMPK is an energy sensor that shuts down anabolic pathways [45] .
Phosphorylation of AMPK inhibits transcriptional activation for adipogenesis, TG synthesis, and FA oxidation [46] . Here, we showed EA promotes AMPK activation during adipogenesis of hASC (Fig. 2E) ; Wang et al. also showed the implication of AMPK activation by EA in 3T3-L1 cells [47] . Consistently, our results showed that upregulation of AMPK phosphorylation by UroA, C, and D attenuated: i) adipogenesis (Fig. 2) ; ii) de novo lipogenesis (gene expressions and metabolic conversion of radiolabeled precursors) and TG esterification (Fig.   3 , 4, 5); and iii) FA oxidation (Fig. 4, 5) . Consistently, the recent animal study showed that punicalagin (ET)-enriched pomegranate consumption prevents obesity associated-cardiac metabolic disorders through AMPK activation [48] . 
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